Amneal Pharmaceuticals, Inc. (AMRX) — Institutional Holders, Q2 2026 (page 4)

312 institutional investment managers reported a AMRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $2.8B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 301 to 312. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

AMRX 13F holders ranked 301–312 of 312

Institutional investors reporting a position in Amneal Pharmaceuticals, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
RAFFA WEALTH MANAGEMENT#301 · 5 sh$87.00+400.0%
Medallion Wealth Advisors#302 · 5 sh$87.00New
DecisionPoint Financial#303 · 5 sh$85.00New
Clearstead Advisors#304 · 4 sh$70.00New
Dunhill Financial#305 · 3 sh$52.000.0%
Steward Partners Investment Advisory#306 · 2 sh$35.00New
MARYLAND CAPITAL ADVISORS#307 · 2 sh$35.00—
GHP Investment Advisors#308 · 1 sh$18.000.0%
Hughes Financial Services#309 · 1 sh$17.000.0%
Capital Advisors, Ltd.#310 · 8 sh$0.000.0%
Navigoe#311 · 6 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#312 · 202,662 sh—-2.2%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.